Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025912 | 1.00 | ALDH1A1 (0.40) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL6209749 | 0.88 | ALDH1A1 (0.36) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL28426667 | 0.83 | OPRM1 (0.40) | ALDH1A1ATMLMNASMN1; SMN2MEN1 | |
| SCHEMBL10957286 | 0.83 | OPRM1 (0.40) | ALDH1A1ATMLMNASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL17393362 | 0.81 | OPRM1 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL17393359 | 0.81 | OPRM1 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL17476070 | 0.78 | OPRM1 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL9274983 | 0.76 | NAAA (0.40) | ALDH1A1TSHRHCAR2NAAAEPHX1 | |
| SCHEMBL2972762 | 0.75 | NPSR1 (0.41) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL10039814 | 0.75 | NPSR1 (0.41) | ALDH1A1LMNAMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| EP-2240475-B1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| EP-2448946-B1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| EP-2448946-A1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | Novartis AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011000855-A1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20100298286-A1 | Organic Compounds | NOVARTIS AG | 2010-11-25 | — | — | US | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| EP-2238134-A2 | BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080705-A2 | BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298286-A1 | Organic Compounds | PIK3CA, PI4KB, PIK3CB | ALDH1A1 1030/4885ATM 377/4885TSHR 4000/4885 |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | PIK3C3, PRKACA, UACA | ALDH1A1 3152/4885ATM 1783/4885TSHR 3213/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | ALDH1A1 1680/4885ATM 467/4885TSHR 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.